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Studying teratogenic effectS of 
medication uSe during pregnancy: 
challengeS and pitfallS
M. Van Gelder*
Department for Health Evidence, Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands
Summary: Depending on the data sources used and the types of stud-
ies included, 29% to 99% of pregnant women in developed countries 
take at least 1 prescribed drug. Although some drugs, such as thalido-
mide and isotretinoin, are classical examples of human teratogens 
(nongenetic risk factors that cause birth defects), the human terato-
genic risks are undetermined for > 90% of prescription drug treat-
ments approved for marketing in the United States since 1980. Due 
to this lack of information, adherence to pharmacologic treatment 
may be discouraged, which may endanger maternal and fetal health, 
or women may choose to terminate their wanted pregnancies based 
on fear of adverse effects. In other pregnancies, fetal development 
may be disturbed by unknown teratogenic exposures that could have 
been avoided. Therefore, high-quality human studies focusing on 
the adverse effects of medication use during pregnancy are urgently 
needed. However, apart from the general methodologic problems in 
epidemiologic research, such as confounding, selection and informa-
tion bias, and limitations in making causal inferences, pharmacoepi-
demiologic studies focusing on birth defects face some important 
problems that are unique to this area of research. During this lecture, 
these problems and some new initiatives in epidemiologic research on 
adverse effects of medication use during pregnancy will be discussed.
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prediction of pharmacological effectS 
of cnS-active agentS during early phaSeS 
of drug development
J. Van Gerven*
Centre for Human Drug Research, Leiden, the Netherlands
Summary: In the last decades, several drugs for neuropsychiatric 
indication failed in late stages of development or were withdrawn 
shortly after launch, including disease-modifying compounds for 
dementia (eg, the γ -secretase inhibitor tarenflurbil) and innovative 
drugs for smoking addiction (eg, the CB1-antagonist rimonabant). A 
few years ago, some of the larger pharmaceutical industries decided 
that the financial risk of developing drugs for psychiatric indications 
was too large, and many CNS projects were abandoned. Currently, 
the industry tries to innovate CNS drug development by investing in 
partnerships with expert groups and exploring novel science-driven 
approaches. An essential requirement for a successful drug is that it 
reaches its therapeutic target in the right concentrations during the 
correct time period, and that it avoids levels or targets associated with 
adverse events. In addition, the drug’s mechanism of action needs to 
have a beneficial effect on the pathogenesis or pathophysiology of 
the disease. Most of these aspects can be accurately determined in 
healthy subjects, in the earliest phases of drug development. To some 
extent this also includes indications of therapeutic benefit, because 
many diseases involve well-known physiological processes that are 
also measurable in normal subjects, although therapeutic benefit can 
only be reliably examined in patients. Thus, the predictions of the 
optimal dosing regimen (or the likeliness of failure) of a new drug in 
patients can be significantly enhanced by demonstration of optimal 
pharmacologic activity in every early (and later) study during drug 
development. This lecture will provide several examples, in which 
pharmacologic effect measurements were incorporated into “tradi-
tional” single and multiple ascending dose studies in Phase I. These 
instruments include (but are not limited to) validated effect biomark-
ers such as the NeuroCart CNS test battery (pharmacologic activity 
and beneficial/detrimental effects), PET measurements or continu-
ous CSF-sampling (BBB-penetration), pharmacologic challenge tests 
(pharmacologic activity) or informative positive controls (bench-
marking), and pharmacokinetic/dynamic analysis for data integra-
tion. The examples involve innovative compounds such as partial 
GABA-A-agonists and CB1-antagonists, and the first human studies 
with a fast-dissociating D2-antagonist and an orexin half-antagonist. 
In most of these cases, traditional approaches were misleading, but a 
goal-directed “question-based” application of pharmacologic tools 
in healthy subjects demonstrated brain penetration and meaningful 
functional effects (indicative of therapeutic or detrimental activity), 
which contributed to accurate predictions of therapeutic windows 
in clinical trials.
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induStry iS more fit for clinical trialS 
than academy
A. Vas*
Head Office, Gedeon Richter Plc, Budapest, Hungary
Summary: Drug R&D is costly, time-consuming, and has a low suc-
cess rate. The costs exceed 1 billion USD. From the human Phase 
I trial on, the increase is exponential. In the EU, 60% of clinical 
trials applied for every year are sponsored by the pharmaceutical 
industry and 40% by other stakeholders, such as academics. It is 
no wonder, then, that the EU Clinical Trials Directive 2011/20/EC 
incented protest mainly from the academic and SME stakeholders. 
According to the EC, although the Directive brought about impor-
tant improvements in the safety and ethical soundness of clinical 
trials and in the reliability of clinical trials data, on the other hand, 
it led to the fall of the number of applications by 25%. The costs 
have increased. The staff needs for industry sponsors to handle the 
clinical trial authorization process have doubled, with SMEs facing 
an even sharper increase. For noncommercial sponsors, the increase 
in administrative requirements has led to a 98% increase in admin-
istrative costs. Insurance fees have increased by 800% for industry 
sponsors. Although the EC is now about to ease the burdens, it is 
clear that significant resources would be required anyhow. The proper 
and time-conscious conduct of extended, multinational, cross-conti-
nental clinical studies requires sufficient high-quality staff, logistics, 
experience, and knowledge of different regulatory aspects, let alone 
a sound financial background. This can be handled only by the help 
of industry resources at the end. Trends and data underpinning this 
opinion will be demonstrated in the presentation.
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collection and impact of patient 
reported outcomeS
A. Viola*
Unité de Pharmaco-Epidémiologie de Lyon, UCBL/CHU de Lyon, 
Lyon, France
Summary: The efficacy assessment in clinical studies evaluating drug 
effects, or more generally disease management, is generally focused 
on the occurrence of objective clinical or economical outcomes, in 
line with regulatory guidelines. However, there is growing recogni-
tion of the value of capturing wider effects of treatments reported by 
patients in the form of patient-reported outcomes (PROs). A PRO 
is defined as any report of the status of a patient’s health condition 
that comes directly from the patient, without interpretation of the 
patient’s response by a clinician or anyone else. After examining the 
reasons explaining the development of these new clinical research 
